Physician profile
Randa Djendou
NPI 1922399856
$6,531.69
in general payments reported to CMS, 2019-2025
43 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $789 · 2021: $671 · 2022: $646 · 2023: $680 · 2024: $1,368 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,113.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $666.41 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $625.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $484.92 | 2019-2025 | |
| Abbott Laboratories | $249.37 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $240.02 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $203.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $188.63 | 2021-2025 | Ubrelvy |
| Merck Sharp & Dohme LLC | $150.35 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.50 | 2019-2022 | |
| Dexcom, INC. | $137.30 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $136.49 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $119.19 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $97.68 | 2019-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $72.05 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randa Djendou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.